Former Pfizer Exec Sees Oligo Drugs Becoming Major Platform Tech in Three Years | GenomeWeb

LAS VEGAS — Despite some recent setbacks, including ones in the RNAi field, oligonucleotide therapeutics are still likely to become the third major drug-development platform alongside small molecules and biologics in a matter of a few years, according to Art Krieg, the former CSO of Pfizer's oligonucleotide therapeutics unit and current president and CEO of RaNA Therapeutics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.